Astellas Oncology

A Selective Approach to R&D

Astellas Oncology pursues targeted therapies for hard-to-treat cancers with limited therapeutic options. Our pipeline includes novel compounds that focus on unmet medical needs.

Astellas Oncology Pipeline

Compound Cancer types Phase
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated. Information displayed is accurate as of May 2015.
Enzalutamide Non-Metastatic CRPC
Enzalutamide Non-Metastatic Biochemical Recurrent PC
Enzalutamide M1 Hormone-Sensitive Prostate Cancer
Gilteritinib AML
Enzalutamide Advanced Breast Cancer
Enzalutamide Hepatocellular Carcinoma
AMG 103 (Blinatumomab) NHL / DLBCL
AMG 103 (Blinatumomab) Acute Lymphoblastic Leukemia
ASP5878 Solid Tumors
ASG-22ME (Enfortumab Vedotin) Urothelial Cancer and Other Malignant Solid Tumors
ASG-15ME Urothelial Cancer

Immuno-Oncology R&D

Astellas Oncology and Potenza Therapeutics, Inc. are collaborating to advance a portfolio of immuno-oncology programs, including compounds with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. First-generation, immuno-oncology products have shown meaningful benefit to patients with certain cancers; the goal of the Astellas Oncology/Potenza collaboration is to address the unmet medical need in patients who do not respond to existing treatments.


Dr. Claire Thom
Senior Vice President
Global Head of Oncology Development

Pipeline for Solid Tumor Cancers

Astellas Oncology and Medivation are evaluating enzalutamide for use as a single agent for the treatment of advanced androgen receptor positive (AR+) triple negative breast cancer (TNBC) as well as hepatocellular carcinoma.

View clinical trials

Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in developing a pipeline of therapeutic fully human monoclonal antibodies (mAbs) to treat cancer. The mAb product pipeline is generated by Agensys' diverse portfolio of proprietary, clinically relevant targets that encompass unmet clinical needs in cancer. Multiple programs are currently undergoing Phase 1 and Phase 2 clinical trials.

View clinical trials